Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 13/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1368883 | 0.81 | LMNA (0.47) | HSD11B1TRPV1 | |
| SCHEMBL1367888 | 0.80 | HSD11B1 (0.46) | HSD11B1TRPV1 | |
| SCHEMBL2031083 | 0.80 | HSD11B1 (0.46) | HSD11B1TRPV1 | |
| SCHEMBL1369593 | 0.79 | EPHX2 (0.66) | EPHX2HSD11B1GAA | |
| SCHEMBL3630668 | 0.76 | EPHX2 (0.66) | EPHX2HSD11B1TRPV1GAA | |
| SCHEMBL1457210 | 0.76 | EPHX2 (0.66) | EPHX2HSD11B1TRPV1GAA | |
| SCHEMBL1734757 | 0.76 | EPHX2 (0.66) | EPHX2HSD11B1TRPV1GAA | |
| SCHEMBL27761289 | 0.76 | HSD11B1 (0.55) | EPHX2HSD11B1TRPV1GAA | |
| SCHEMBL4266990 | 0.74 | TRPV1 (0.69) | EPHX2HSD11B1TRPV1GAA | |
| Trifluoroacetic Acid SCHEMBL15655268 | 0.73 | DPP4 (0.48) | HSD11B1TRPV1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288129-A1 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | US | disclosed |
| US-7998982-B2 | Amide derivatives as TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-08-16 | — | — | US | disclosed |
| US-20090062345-A1 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062345-A1 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPA1 | EPHX2 912/4885HSD11B1 3218/4885TRPV1 1/4885 |
| US-20110288129-A1 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPA1 | EPHX2 912/4885HSD11B1 3218/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.